Vancomycin remains the prototypical glycopeptide antibiotic and the backbone of therapy for methicillin-resistant Staphylococcus aureus (MRSA) and other serious Gram-positive infections. Its mechanism is distinct from beta-lactams, and its pharmacokinetic (PK) complexity demands individualized dosing supported by therapeutic drug monitoring (TDM).1
Vancomycin exerts bactericidal activity by binding with high affinity to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursor units (lipid II) on the outer surface of the bacterial cell membrane.1 This steric blockade physically prevents transglycosylation and transpeptidation, the two enzymatic steps required to cross-link nascent peptidoglycan strands into a mechanically stable cell wall. Because vancomycin acts on a lipid-anchored substrate outside the cell rather than on an intracellular enzyme, it is unaffected by the penicillin-binding protein (PBP) alterations that confer methicillin resistance, which is precisely why vancomycin retains activity against MRSA while all beta-lactams except ceftaroline fail. The glycopeptide scaffold is a large tricyclic heptapeptide (approximately 1,450 Da) whose size alone precludes penetration through the outer membrane porins of Gram-negative bacteria, explaining the intrinsic absence of Gram-negative activity.
The antibacterial spectrum of vancomycin is confined entirely to Gram-positive organisms. It is reliably active against MRSA, methicillin-susceptible S. aureus (MSSA), coagulase-negative staphylococci, Streptococcus pneumoniae (including penicillin-resistant strains), viridans streptococci, Streptococcus pyogenes, and Enterococcus faecalis.4 Enterococcus faecium is intrinsically less susceptible and may be vancomycin-resistant (vancomycin-resistant enterococcus, or VRE). When given orally, vancomycin is not absorbed from the gastrointestinal (GI) tract and achieves extremely high intraluminal concentrations, making it one of the treatments of choice for severe or recurrent Clostridioides difficile infection via the oral route. This represents a pharmacokinetically distinct application: oral vancomycin acts entirely locally and does not contribute to systemic drug levels.
Vancomycin is not absorbed after oral administration and must be given intravenously (IV) for systemic infections. After IV infusion, it distributes widely into body fluids and tissues, with an apparent volume of distribution (Vd) of approximately 0.4 to 1.0 L/kg.3 Protein binding is approximately 50 to 55 percent, predominantly to albumin. Tissue penetration is generally adequate for most infection sites, though cerebrospinal fluid (CSF) penetration is limited under normal conditions (approximately 10 to 20 percent of serum levels), improving somewhat with inflamed meninges. The drug undergoes negligible hepatic metabolism; elimination is almost entirely via glomerular filtration (GFR) in the kidney, with a half-life of approximately 4 to 8 hours in patients with normal renal function. In patients with severe renal impairment or end-stage renal disease (ESRD), the half-life can extend to 200 hours or more, necessitating marked dose interval prolongation.
The pharmacodynamic (PD) index that best predicts vancomycin efficacy is the ratio of the area under the concentration-time curve over 24 hours to the minimum inhibitory concentration (AUC24/MIC). For MRSA infections, an AUC24/MIC target of 400 to 600 mg-h/L is associated with optimal clinical outcomes and is endorsed by the 2019 joint guidelines from the American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), and Society of Infectious Diseases Pharmacists (SIDP).4 This target replaced the prior practice of trough-only monitoring, which had been used as a surrogate for AUC but proved imprecise, leading to both underdosing (treatment failure) and overdosing (nephrotoxicity). AUC-guided dosing requires either Bayesian pharmacokinetic software using two timed serum samples or a validated two-point sampling strategy around the first or second dose, depending on the institution.
Oral vancomycin for C. diff acts entirely locally and produces no systemic levels. IV vancomycin for MRSA bacteremia does not achieve meaningful intraluminal GI concentrations. These are pharmacokinetically separate routes with non-overlapping applications. Never substitute one for the other.
Vancomycin dosing is weight-based, with total body weight used to calculate the loading and maintenance doses. Standard initial dosing is typically 15 to 20 mg/kg IV every 8 to 12 hours, but dose and interval must be individualized based on renal function, body weight, and the AUC target.3 Loading doses of 25 to 30 mg/kg are recommended for patients with severe sepsis to achieve therapeutic concentrations rapidly, given the relatively long time to steady-state with standard dosing. Each infusion should be administered over at least 60 minutes, and preferably longer for doses exceeding 1,000 mg, to reduce the risk of infusion-related reactions.
Vancomycin's adverse effect profile centers on nephrotoxicity and infusion-related reactions, with ototoxicity representing a less common but clinically significant concern. The shift to area under the concentration-time curve (AUC)-guided therapeutic drug monitoring (TDM) was driven largely by the recognition that trough-based monitoring was associated with excess nephrotoxicity without consistently improving efficacy.4
Nephrotoxicity is the most clinically significant adverse effect of vancomycin, arising from oxidative stress and mitochondrial dysfunction in proximal tubular cells, leading to tubular injury.6 Risk is strongly associated with the magnitude and duration of drug exposure: prolonged courses, high trough concentrations (particularly sustained troughs above 15 to 20 mcg/mL under the prior monitoring paradigm), and concomitant use of nephrotoxic agents all amplify risk. The combination of vancomycin with piperacillin-tazobactam has been associated with significantly increased rates of acute kidney injury (AKI) compared to vancomycin alone or with other beta-lactams, a finding that prompted widespread reconsideration of this combination in empiric regimens.6 AKI from vancomycin is generally reversible upon dose reduction or discontinuation, but monitoring of serum creatinine and urine output is mandatory during therapy. Under AUC-guided dosing, the target AUC24/minimum inhibitory concentration (MIC) of 400 to 600 keeps exposure within a range associated with lower nephrotoxicity rates compared to the trough-only era.
Red man syndrome (RMS) is an infusion-related reaction caused by vancomycin-induced non-immune mast cell degranulation and direct histamine release, producing flushing, erythema, and pruritus predominantly over the face, neck, and upper torso.7 It is rate-dependent rather than dose-dependent in the traditional allergic sense: slower infusion rates substantially reduce or eliminate the reaction. RMS is not a true immunoglobulin E (IgE)-mediated hypersensitivity reaction and does not predict anaphylaxis or contraindicate future vancomycin use. Pretreatment with diphenhydramine (an H1 antihistamine) and extending the infusion time to 90 to 120 minutes are the primary management strategies. Patients labeled as vancomycin-allergic due to RMS are unnecessarily deprived of a critical antibiotic; proper characterization of the reaction type is mandatory before any allergy designation is applied.
Ototoxicity, encompassing both cochlear toxicity (sensorineural hearing loss) and vestibular toxicity, is a recognized but less common adverse effect of vancomycin.8 Historical data implicating vancomycin as a primary ototoxin were complicated by the frequent concomitant use of aminoglycosides, which are independently ototoxic. When vancomycin is used without aminoglycosides, ototoxicity risk appears low at standard dosing. Risk factors include prolonged high-dose therapy, renal impairment causing drug accumulation, and concomitant aminoglycoside use. Audiometric monitoring is not routinely recommended unless the patient has pre-existing hearing loss, receives prolonged therapy, or develops symptoms such as tinnitus or hearing change during treatment.
The 2019 American Society of Health-System Pharmacists (ASHP)/Infectious Diseases Society of America (IDSA)/Society of Infectious Diseases Pharmacists (SIDP) consensus guidelines represent a landmark shift in vancomycin TDM practice.4 The prior standard of trough-only monitoring targeted troughs of 15 to 20 mcg/mL for serious methicillin-resistant Staphylococcus aureus (MRSA) infections as a surrogate for achieving AUC targets, but this approach was shown to be imprecise: many patients with troughs in this range had AUC values either below 400 (insufficient) or above 600 (unnecessarily toxic). The guidelines now recommend AUC-based monitoring using Bayesian pharmacokinetic (PK) software as the preferred method, with two timed serum samples used to individualize the PK estimate. The target AUC24/MIC of 400 to 600 mg-h/L assumes an MRSA MIC of 1 mcg/mL, which encompasses the vast majority of clinical MRSA isolates. For organisms with MIC values of 2 mcg/mL or above, achieving the target AUC without exceeding tolerable serum concentrations becomes problematic, and alternative agents should be considered.
AUC-guided dosing requires two timed samples and Bayesian software at most centers. If Bayesian tools are unavailable, trough-only monitoring with a target of 15 to 20 mcg/mL remains acceptable for serious infections but is associated with higher nephrotoxicity rates. Renal function must be reassessed at least every 48 to 72 hours and doses adjusted promptly with any change in creatinine clearance. Discontinue or dose-reduce early if AKI develops.
Vancomycin resistance in S. aureus occurs through two distinct mechanisms with very different clinical implications. Vancomycin-intermediate S. aureus (VISA) strains have MIC values of 4 to 8 mcg/mL and emerge through gradual cell wall thickening caused by point mutations in regulatory genes (particularly walKR and vraSR), which increases the number of D-Ala-D-Ala targets that must be saturated before effective cell wall inhibition is achieved.9 VISA frequently arises after prolonged vancomycin exposure and may be preceded by heterogeneous VISA (hVISA), in which only a subpopulation of cells demonstrates intermediate resistance. Vancomycin-resistant S. aureus (VRSA) strains, carrying the vanA gene complex acquired from vancomycin-resistant enterococcus (VRE) via conjugation, are rare but confer high-level resistance (MIC above 16 mcg/mL) through substitution of D-Ala-D-Ala with D-alanyl-D-lactate (D-Ala-D-Lac), eliminating vancomycin binding affinity. VRSA infections require consultation with infectious disease specialists and use of alternative agents such as linezolid or daptomycin.
Second-generation glycopeptides were developed to address the pharmacokinetic (PK) limitations of vancomycin, particularly its requirement for intravenous (IV) administration with frequent dosing and intensive monitoring. Their markedly extended half-lives enable once-weekly or even single-dose regimens that have transformed the outpatient management of serious Gram-positive infections.10
Teicoplanin is a naturally occurring glycopeptide closely related to vancomycin in its mechanism, binding D-Ala-D-Ala termini to inhibit peptidoglycan synthesis.10 It differs from vancomycin in having a lipophilic side chain that anchors it to the bacterial membrane, improving potency against some strains. Its half-life of approximately 70 to 100 hours permits once-daily intramuscular (IM) or IV dosing after an initial loading regimen, a significant convenience advantage over vancomycin. Teicoplanin is widely used in Europe and other regions but is not approved in the United States. Adverse effects are similar to vancomycin but red man syndrome (RMS) is less frequent, and nephrotoxicity rates appear somewhat lower. Therapeutic drug monitoring (TDM) is still recommended, targeting trough concentrations of 15 to 30 mcg/mL for serious infections. Teicoplanin retains activity against most vancomycin-susceptible strains but is susceptible to vanA-mediated resistance, unlike oritavancin which retains partial vanA activity.
Dalbavancin is a semisynthetic lipoglycopeptide with an exceptionally long half-life of approximately 346 to 374 hours (roughly 14 to 15 days), enabling a two-dose regimen (1,500 mg as a single dose, or 1,000 mg followed by 500 mg one week later) for acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA).11 Its mechanism involves D-Ala-D-Ala binding combined with membrane anchoring via a lipophilic side chain, producing concentration-dependent bactericidal activity. Dalbavancin allows patients to complete a full course of therapy with one or two infusions rather than 10 to 14 days of daily vancomycin, enabling earlier hospital discharge or avoiding hospitalization entirely, making it particularly attractive for outpatient parenteral antibiotic therapy (OPAT) programs. It does not require TDM and has no known clinically significant drug interactions. Dose adjustment is required for creatinine clearance below 30 mL/min in patients not on hemodialysis.
Oritavancin is another semisynthetic lipoglycopeptide distinguished by a unique triple mechanism of action: D-Ala-D-Ala binding (shared with vancomycin), inhibition of transglycosylation through a secondary binding site, and disruption of bacterial membrane integrity through its lipophilic tail.12 This triple mechanism results in rapid concentration-dependent bactericidal activity and retention of partial activity against vanA-expressing vancomycin-resistant enterococcus (VRE) strains, unlike vancomycin and dalbavancin. Oritavancin's half-life of approximately 245 hours enables a single 1,200 mg dose to treat ABSSSI, the most simplified dosing regimen among all glycopeptides. The membrane-disrupting component also confers activity against biofilm-embedded organisms, a property with potential utility in device-related infections, though formal approvals are limited to ABSSSI. Oritavancin interferes with activated partial thromboplastin time (aPTT), prothrombin time (PT), and activated clotting time (ACT) assays for up to 120 hours after dosing, complicating anticoagulation monitoring in patients who require it.
Telavancin is a semisynthetic lipoglycopeptide approved for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Gram-positive pathogens and for complicated skin and skin structure infections (cSSSI).10 Like oritavancin, it combines D-Ala-D-Ala binding with membrane depolarization, producing rapid bactericidal activity. Its half-life of approximately 8 hours requires once-daily IV dosing. Telavancin carries a black box warning for nephrotoxicity, which occurs at rates higher than vancomycin in some clinical trials, limiting its use to situations where alternative agents are unsuitable. It is also teratogenic in animal studies and a negative pregnancy test is required before initiation in women of childbearing potential. Like oritavancin, telavancin interferes with coagulation assays and these values should not be interpreted as reflecting actual hemostatic status during therapy.
Dalbavancin (single dose or two doses one week apart) and oritavancin (single dose) are the primary agents for OPAT simplification in ABSSSI. Neither requires TDM. Oritavancin's partial vanA activity and biofilm penetration are additional differentiators. Teicoplanin is once-daily and widely used outside the US. Telavancin is reserved for pneumonia or cSSSI when alternatives are unsuitable, given its nephrotoxicity profile.
Daptomycin is the prototype and only approved member of the lipopeptide class. Its mechanism of action (MOA) is entirely distinct from all other antibacterials, operating through calcium-dependent membrane depolarization rather than cell wall or protein synthesis inhibition. This mechanistic uniqueness makes it effective against many glycopeptide-resistant organisms, but a critical pharmacokinetic (PK) limitation, inactivation by pulmonary surfactant, absolutely prohibits its use in pneumonia.13
Mechanism of action. Daptomycin requires calcium (Ca2+) for activation. In the presence of physiologic calcium concentrations, the drug inserts its lipophilic tail into the bacterial cytoplasmic membrane and oligomerizes to form ion-conducting channels, causing rapid membrane depolarization and dissipation of the transmembrane electrical potential.13 This disruption arrests deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and protein synthesis simultaneously by collapsing the electrochemical gradient that drives these processes, resulting in rapid concentration-dependent bactericidal activity without cell lysis. Because the mechanism targets the cytoplasmic membrane directly rather than a biosynthetic enzyme, cross-resistance with cell wall agents (vancomycin, beta-lactams) or protein synthesis inhibitors (linezolid, macrolides) is not expected at the mechanistic level, though acquired resistance can still emerge.
Spectrum and dosing. Daptomycin is active against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible S. aureus (MSSA), vancomycin-resistant enterococcus (VRE) (both E. faecalis and E. faecium), vancomycin-intermediate S. aureus (VISA), and many strains of vancomycin-resistant S. aureus (VRSA).2 It is one of the primary options for VRE bacteremia and enterococcal endocarditis when vancomycin resistance precludes first-line therapy. Daptomycin demonstrates concentration-dependent killing and the pharmacodynamic index correlating with efficacy is the area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) ratio. Doses of 6 mg/kg/day are standard for bacteremia and right-sided endocarditis; doses of 8 to 10 mg/kg/day or higher have been used for more difficult infections such as left-sided endocarditis or osteomyelitis, though these higher doses are not formally approved.
Pharmacokinetics. Daptomycin is administered IV once daily with a half-life of approximately 8 to 9 hours in patients with normal renal function.13 Protein binding is approximately 90 to 93 percent. Volume of distribution (Vd) is approximately 0.1 L/kg, reflecting limited extravascular distribution, an important consideration when treating infections in poorly perfused compartments. Elimination is primarily renal; dose adjustment is required when creatinine clearance (CrCl) falls below 30 mL/min, with a standard adjustment to every 48-hour dosing in severe renal impairment. Daptomycin is removed by hemodialysis and supplemental doses may be required after sessions depending on the dialysis membrane and session duration.
Surfactant inactivation. Surfactant components, particularly phosphatidylglycerol, bind daptomycin and prevent its insertion into bacterial membranes, completely abolishing antibacterial activity within the alveolar space.14 This pharmacodynamic antagonism is absolute: daptomycin must never be used to treat pneumonia, regardless of the causative organism's in vitro susceptibility. Susceptibility testing may report an MRSA isolate as daptomycin-susceptible, but in vivo the drug will fail entirely if the infection is pulmonary. Linezolid or vancomycin remain the agents of choice for MRSA pneumonia. This surfactant inactivation principle is one of the most clinically consequential facts in antibacterial pharmacology and must be internalized before prescribing this agent.
Adverse effects. The principal adverse effect of daptomycin is skeletal muscle toxicity, manifesting as myopathy with elevation of creatine phosphokinase (CPK) and, rarely, rhabdomyolysis with myoglobinuria and acute kidney injury (AKI).15 CPK should be monitored weekly during therapy, and daptomycin should be discontinued if CPK rises above five times the upper limit of normal (ULN) with symptoms or ten times the ULN regardless of symptoms. Concomitant use of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) increases myopathy risk and statin therapy should be suspended during daptomycin courses where possible. Peripheral neuropathy has been reported with prolonged use. Eosinophilic pneumonia, a paradoxical pulmonary toxicity distinct from the surfactant-inactivation phenomenon, has been described with daptomycin and should be considered if a patient develops new pulmonary infiltrates and eosinophilia during therapy.
Resistance. Daptomycin resistance emerges primarily through alterations in cell membrane phospholipid composition that reduce the affinity of daptomycin for its membrane target. Mutations in mprF (which encodes lysyl-phosphatidylglycerol synthetase) increase the positive charge of the membrane surface, electrostatically repelling the negatively charged calcium-daptomycin complex before insertion can occur.5 Mutations in yycFG, rpoBC, and genes governing cell wall thickness also contribute. A well-documented clinical phenomenon is the emergence of daptomycin non-susceptible MRSA (DNS-MRSA) following prolonged vancomycin exposure, even without prior daptomycin use.5 The cell wall thickening that characterizes VISA simultaneously reduces daptomycin's ability to reach and insert into the cytoplasmic membrane. This "see-saw" effect, increasing vancomycin minimum inhibitory concentration (MIC) paralleling increasing daptomycin MIC, means that heavily vancomycin-exposed patients may not be reliably salvageable with daptomycin if their MRSA isolate has already developed intermediate vancomycin resistance. Susceptibility testing for daptomycin is essential before relying on it for salvage therapy.
Never use daptomycin for pneumonia: surfactant inactivation is absolute and in vitro susceptibility is irrelevant. Monitor CPK weekly; suspend statins. For MRSA bacteremia or endocarditis, daptomycin at 6 mg/kg/day or higher is a first-line alternative to vancomycin. Test daptomycin susceptibility before using as salvage after vancomycin failure; the see-saw effect may have already compromised activity.
Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat Rev Drug Discov. 2006;5(4):321–332.
doi:10.1038/nrd2004Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665.
doi:10.1056/NEJMoa053783Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25(4):433–437.
doi:10.1128/AAC.25.4.433Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864.
doi:10.1093/ajhp/zxaa036Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50(4):1581–1585.
doi:10.1128/AAC.50.4.1581-1585.2006Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64(2):116–123.
doi:10.1093/cid/ciw709Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119–120.
doi:10.1186/cc1871Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138–2144.
doi:10.1001/archinte.166.19.2138Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99–139.
doi:10.1128/CMR.00042-09Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–886.
doi:10.2165/11534440-000000000-00000Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179.
doi:10.1056/NEJMoa1310480Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54(12):5369–5371.
doi:10.1128/AAC.00760-10Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55(3):283–288.
doi:10.1093/jac/dkh546Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149–2152.
doi:10.1086/430352Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568–1574.
doi:10.1086/652767